The BRAVE Coalition Foundation has received a significant donation from Johnson & Johnson, reinforcing the healthcare company's commitment to supporting breast cancer survivors and advancing patient-centered reconstruction education. This contribution represents the continuation of Johnson & Johnson's support for the BRAVE Coalition, which began in 2018, and reflects a shared dedication to empowering women with knowledge, advocacy, and access throughout their breast reconstruction journey.
Johnson & Johnson's ongoing support advances BRAVE Coalition's mission of advocacy, education, and equitable access, ensuring women have the resources and support they need to make informed decisions about their bodies and their recovery following breast cancer. "Support like this allows us to expand our reach and deepen our impact," said Lisa Shumpert, President of BRAVE Coalition Foundation. "Johnson & Johnson's continued investment in our mission underscores the importance of standing beside patients—not just during treatment, but throughout their entire reconstruction and healing process."
Through initiatives including patient education programs, surgeon collaboration, community outreach, and survivor resources, BRAVE Coalition works to remove barriers to care and elevate awareness around breast reconstruction options regardless of insurance coverage or socio-economic status. This contribution will help further these efforts, enabling BRAVE Coalition to continue advocating for informed choice, access, and empowerment for breast cancer survivors nationwide.
The BRAVE Coalition Foundation, founded in 2012 by Dr. Allen Gabriel and Dr. Christine Grogan, is dedicated to promoting education and awareness about resources for breast cancer survivors concerning breast reconstruction options. The organization believes every woman should have the right to decide how they shape their recovery from breast cancer. To learn more about the foundation's work, visit https://www.bravecoalition.org.
This development matters because it addresses critical gaps in post-cancer care where many survivors face significant barriers to reconstruction options. The financial support enables expanded educational programs that directly impact patient outcomes by ensuring women have comprehensive information about their choices. For the healthcare industry, it represents corporate partnership in addressing disparities in cancer care access, while for patients, it means more resources during a vulnerable recovery period. The ongoing nature of Johnson & Johnson's support since 2018 demonstrates sustained commitment to this issue rather than one-time charitable giving.
